BACKGROUND: Viral bronchiolitis is the leading cause of respiratory failure among infants in the United States. Currently, the mainstay of treatment is supportive care. The effectiveness of treatments used for mechanically ventilated infants with bronchiolitis is unclear. OBJECTIVE: To evaluate the strength of the evidence supporting the use of currently available treatments for critically ill infants with bronchiolitis. DATA SOURCE: We searched PubMed, citations of relevant articles, personal files, and conference proceedings, and we contacted experts in the field. STUDY SELECTION: Randomized, controlled trials evaluating any therapy for bronchiolitis that included children in an intensive care unit. DATA EXTRACTION: Two reviewers independently extracted data and assessed methodologic quality. DATA SYNTHESIS: A total of 2,319 citations were screened, and 16 randomized, controlled trials were included. There were three trials of surfactant, three of ribavirin, three of immune globulin, three of systemic corticosteroids, and one each of vitamin A, interferon, erythropoietin, and heliox. A meta-analysis of the three surfactant studies showed a strong trend toward a decrease in duration of mechanical ventilation of 2.58 days (95% confidence interval, -5.34 to 0.18 days; p =.07) and a significant decrease of 3.3 intensive care unit days (95% confidence interval, -6.38 to -0.23 days; p =.04). A meta-analysis of the three systemic corticosteroid studies showed no overall effect on duration of mechanical ventilation when all three trials were combined (-0.62 day; 95% confidence interval, -2.78 to 1.53 days; p =.57). We identified one published meta-analysis of three ribavirin studies showing a significant decrease in ventilator days with ribavirin (-1.2 days; 95% confidence interval, -0.2 to -3.4 days; p =.2). CONCLUSIONS: Currently, there are no clearly effective interventions available to improve the outcome of critically ill infants with bronchiolitis. Surfactant seems to be a promising intervention, and corticosteroids or ribavirin may also be beneficial.
BACKGROUND:Viral bronchiolitis is the leading cause of respiratory failure among infants in the United States. Currently, the mainstay of treatment is supportive care. The effectiveness of treatments used for mechanically ventilated infants with bronchiolitis is unclear. OBJECTIVE: To evaluate the strength of the evidence supporting the use of currently available treatments for critically ill infants with bronchiolitis. DATA SOURCE: We searched PubMed, citations of relevant articles, personal files, and conference proceedings, and we contacted experts in the field. STUDY SELECTION: Randomized, controlled trials evaluating any therapy for bronchiolitis that included children in an intensive care unit. DATA EXTRACTION: Two reviewers independently extracted data and assessed methodologic quality. DATA SYNTHESIS: A total of 2,319 citations were screened, and 16 randomized, controlled trials were included. There were three trials of surfactant, three of ribavirin, three of immune globulin, three of systemic corticosteroids, and one each of vitamin A, interferon, erythropoietin, and heliox. A meta-analysis of the three surfactant studies showed a strong trend toward a decrease in duration of mechanical ventilation of 2.58 days (95% confidence interval, -5.34 to 0.18 days; p =.07) and a significant decrease of 3.3 intensive care unit days (95% confidence interval, -6.38 to -0.23 days; p =.04). A meta-analysis of the three systemic corticosteroid studies showed no overall effect on duration of mechanical ventilation when all three trials were combined (-0.62 day; 95% confidence interval, -2.78 to 1.53 days; p =.57). We identified one published meta-analysis of three ribavirin studies showing a significant decrease in ventilator days with ribavirin (-1.2 days; 95% confidence interval, -0.2 to -3.4 days; p =.2). CONCLUSIONS: Currently, there are no clearly effective interventions available to improve the outcome of critically ill infants with bronchiolitis. Surfactant seems to be a promising intervention, and corticosteroids or ribavirin may also be beneficial.
Authors: Suzanne Schuh; Allan L Coates; Rosemary Binnie; Tracey Allin; Cristina Goia; Mary Corey; Paul T Dick Journal: J Pediatr Date: 2002-01 Impact factor: 4.406
Authors: R T Stein; D Sherrill; W J Morgan; C J Holberg; M Halonen; L M Taussig; A L Wright; F D Martinez Journal: Lancet Date: 1999-08-14 Impact factor: 79.321
Authors: E E Wang; B J Law; F D Boucher; D Stephens; J L Robinson; S Dobson; J M Langley; J McDonald; N E MacDonald; I Mitchell Journal: J Pediatr Date: 1996-09 Impact factor: 4.406
Authors: Adrienne G Randolph; Kathleen L Meert; Mary E O'Neil; James H Hanson; Peter M Luckett; John H Arnold; Rainer G Gedeit; Peter N Cox; Joan S Roberts; Shekhar T Venkataraman; Peter W Forbes; Ira M Cheifetz Journal: Am J Respir Crit Care Med Date: 2003-02-25 Impact factor: 21.405
Authors: Marco Luchetti; Federica Ferrero; Carla Gallini; Alfonso Natale; Antonia Pigna; Luca Tortorolo; Giuseppe Marraro Journal: Pediatr Crit Care Med Date: 2002-07 Impact factor: 3.624
Authors: Rachael M Liesman; Ursula J Buchholz; Cindy L Luongo; Lijuan Yang; Alan D Proia; John P DeVincenzo; Peter L Collins; Raymond J Pickles Journal: J Clin Invest Date: 2014-04-08 Impact factor: 14.808
Authors: Ed Oakley; Franz E Babl; Jason Acworth; Meredith Borland; David Kreiser; Jocelyn Neutze; Theane Theophilos; Susan Donath; Mike South; Andrew Davidson Journal: BMC Pediatr Date: 2010-06-01 Impact factor: 2.125
Authors: Zahara Nizarali; Marta Cabral; Catarina Silvestre; Clara Abadesso; Pedro Nunes; Helena Loureiro; Helena Almeida Journal: Rev Bras Ter Intensiva Date: 2012-12
Authors: Ian C Davis; Eduardo R Lazarowski; Fu-Ping Chen; Judy M Hickman-Davis; Wayne M Sullender; Sadis Matalon Journal: Am J Respir Cell Mol Biol Date: 2007-05-31 Impact factor: 6.914